Clinical trials: Cytokine Release Syndrome
Covid19 Pneumonia
The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation
Title: The use of Tocilizumab in the management of patients who have severe COVID-19 with suspected pulmonary hyperinflammation.
- Trial name
- NCT04377750
- Testing
- Tocilizumab
- Where
- 4 sites in Israel
- Volunteers
- 500 people
- Sponsor
- Hadassah Medical Organization
Cytokine Release Syndrome, Recurrent Multiple Myeloma
Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma
This phase II trial tests how well giving infliximab works for the prevention of cytokine release syndrome (CRS) during treatment with teclistamab or talquetamab in patients with multiple myeloma that has come back after a period…
- Conditions
- Cytokine Release Syndrome, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
- Trial name
- NCT07657312
- Testing
- Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Naresh Bumma
Lymphohistiocytosis, Hemophagocytic, Secondary Hemophagocytic Lymphohistiocytosis
Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE Study
Background: Hemophagocytic lymphohistiocytosis (HLH) is a disease caused by disrupted immune function. People with HLH are prone to fevers and illnesses, which can be fatal.
- Conditions
- Lymphohistiocytosis, Hemophagocytic, Secondary Hemophagocytic Lymphohistiocytosis, Macrophage Activation Syndrome, Hyperinflammatory Syndromes
- Trial name
- NCT06339177
- Where
- 2 sites in United States
- Volunteers
- 300 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Acute Respiratory Distress Syndrome, Inflammation
Dexmedetomidine to Improve Outcomes of ARDS in Critical Care COVID-19 Patients
A continuous infusion of Dexmedetomidine (DEX) will be administered to 80 patients admitted to Critical Care because of signs of Respiratory Insufficiency requiring non-invasive ventilation.
- Conditions
- Acute Respiratory Distress Syndrome, Inflammation, Dexmedetomidine, Cytokine Storm
- Trial name
- COVID-DEX (NCT04358627)
- Testing
- Dexmedetomidine Injectable Product
- Volunteers
- 80 people
- Sponsor
- Hospital Clinic of Barcelona
COVID-19, Cytokine Storm
CORONA: A Study Using DeltaRex-G Gene Therapy for Symptomatic COVID-19
COVID-19 is an infectious disease caused by severe acute respiratory syndrome coronavirus 2. COVID-19 causes life threatening complications known as Cytokine Release Syndrome or Cytokine Storm and Acute Respiratory Distress…
- Conditions
- COVID-19, Cytokine Storm, Acute Respiratory Distress Syndrome
- Trial name
- CORONA (NCT04378244)
- Testing
- DeltaRex-G
- Sponsor
- Aveni Foundation
Celiac Disease
Gluten Challenge in Celiac Disease - Which Formulation of Gluten Gives the Best Response?
The goal of this clinical trial is to evaluate the immune response to gluten in patients with celiac disease (CeD) by comparing different forms of gluten administration.
- Trial name
- SHAKE (NCT07039773)
- Testing
- Vital wheat gluten
- Where
- 2 sites in Norway
- Volunteers
- 30 people
- Sponsor
- Oslo University Hospital
COVID-19, COVID-19 Pneumonia
Study to Verify the Effectiveness and Safety of Isothymol or Carvacrol Compound Against SARS-CoV-2 in COVID-19 Patients
Check the efficacy, safety and tolerability of the compound Modified isothymol against the SARS-CoV-2 agent in patients COVID-19.
- Conditions
- COVID-19, COVID-19 Pneumonia, COVID-19 Respiratory Infection, COVID-19 Acute Respiratory Distress Syndrome
- Trial name
- NCT05445089
- Testing
- Carvacrol, Control group
- Where
- Venezuela
- Volunteers
- 600 people
- Sponsor
- Instituto Venezolano de Investigaciones Cientificas
COVID-19, SARS
Modulation of Hyperinflammation in COVID-19
Current treatment recommendations are based on very limited evidence and reliant on the deployment of pharmacological strategies of doubtful efficacy, high toxicity, and near universal shortages of supply.
- Trial name
- NCT04353674
- Testing
- Control group, SLEDD with a L-MOD
- Where
- 2 sites in Canada
- Volunteers
- 12 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Sepsis, Sepsis Bacterial
Clinical Outcomes and Inflammatory Responses in Viral vs. Bacterial Sepsis
This observational cohort study aims to compare clinical outcomes and inflammatory responses between patients with viral sepsis, specifically COVID-19-associated sepsis, and those with bacterial sepsis.
- Conditions
- Sepsis, Sepsis Bacterial, Viral Sepsis, Inflammatory Response
- Trial name
- NCT06491966
- Testing
- observation
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Sichuan Provincial People's Hospital
Severe COVID-19 Disease
RAPA-501-Allo Therapy of COVID-19-ARDS
The first-in-human Phase 1 study component will evaluate two dose levels of RAPA-501-ALLO off the shelf cells in patients with COVID-19-related ARDS, with key endpoints of safety, biologic and potential disease-modifying effects.
- Trial name
- NCT04482699
- Testing
- RAPA-501-Allo off-the-shelf Therapy of COVID-19
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Rapa Therapeutics LLC
Rhabdomyolysis, Acute Liver Injury
Prospective Study for the Application of Cytosorb® in Critically Ill Patients
The mortality of critically ill patients is persistently high and requires targeted therapy of pathophysiological disorders. One approach to optimize therapy is the use of the cytokine adsorber Cytosorb®, which has a CE…
- Conditions
- Rhabdomyolysis, Acute Liver Injury, Cytokine Storm
- Trial name
- Cyto-SOLVE (NCT04913298)
- Testing
- Cytosorb therapy
- Where
- Germany
- Volunteers
- 57 people
- Sponsor
- Ludwig-Maximilians - University of Munich
SARS-CoV-2 Respiratory Failure
Blood Ozonization in Patients With SARS-CoV-2 Respiratory Failure
Aim. The emerging outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread worldwide.
- Trial name
- CORMOR (NCT04388514)
- Testing
- Medical Ozone procedure
- Where
- Italy
- Volunteers
- 90 people
- Sponsor
- Azienda Sanitaria-Universitaria Integrata di Udine
Burns, Multiple Organ Failure
Early Haemadsorption in Major Burns
Major deep burns (>20% body surface, involving deep skin layers) and associated severe inflammatory reaction and their complication are one of the biggest challenge of intensive care.
- Conditions
- Burns, Multiple Organ Failure, Shock, Organ Dysfunction Syndrome, Multiple
- Trial name
- NCT04195126
- Testing
- CytoSorb haemadsorption device
- Where
- Hungary
- Volunteers
- 20 people
- Sponsor
- University of Pecs
COVID-19
Safety and Efficacy of Baricitinib for COVID-19
This study plans to learn more about the effects of a medicine called baricitinib on the progression of COVID-19 (coronavirus disease of 2019), the medical condition caused by the Severe Acute Respiratory Syndrome Coronavirus 2…
- Trial name
- NCT04340232
- Testing
- Baricitinib
- Where
- United States
- Sponsor
- University of Colorado, Denver
DHA as Antioxidant Anti-inflammatory Immunomodulation , Overcome Cytokine Storm
Observational Study of Infants Fed on DHA (Breast Source or Milk Formula Source ) and Its Effects on Covid-19 Infected Infants and Severity
Observational Study of Infants Fed on DHA (Breast Source or Milk Formula Source ) and Its Effect on COVID-19 Severity Amr kamel khalil Ahmed ( drmedahmed@gmail.com ) Director of tuberculosis program Ghubera, public health…
- Trial name
- NCT05071690
- Where
- 2 sites in Egypt, Saudi Arabia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Ministry of Health, Saudi Arabia
Acute Respiratory Distress Syndrome, Coronavirus
Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).
This is a multicenter, randomized, double-blind, parallel group study to investigate the efficacy of pemziviptadil (PB1046) by improving the clinical outcomes in hospitalized COVID-19 patients at high risk for rapid clinical…
- Conditions
- Acute Respiratory Distress Syndrome, Coronavirus, Hypoxic Respiratory Failure, Hypoxemic Respiratory Failure
- Trial name
- VANGARD (NCT04433546)
- Testing
- Pemziviptadil (PB1046), Low Dose (10 mg) Control
- Where
- 4 sites in United States
- Volunteers
- 54 people
- Sponsor
- PhaseBio Pharmaceuticals Inc.
COVID-19
Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib in the treatment of participants with COVID-19-associated Acute Respiratory Distress Syndrome (ARDS) who require mechanical ventilation.
- Trial name
- NCT04377620
- Testing
- Ruxolitinib
- Where
- 36 sites in United States, Russia
- Volunteers
- 211 people
- Sponsor
- Incyte Corporation
Heart; Dysfunction Postoperative, Cardiac Surgery, Cytokine Release Syndrome
Study of the Clinical Scoring System and Cytokines for Prediction of Inflammatory Response in Major Surgery
Cardiac surgery with cardiopulmonary bypass (CPB) and hepatic surgery are major operations, associated with a systemic inflammatory response syndrome.
- Trial name
- NCT01353157
- Where
- Thailand
- Volunteers
- 20 people
- Sponsor
- Khon Kaen University
Sepsis, Septic Shock
Influence of Cytosorb on Amount of Catecholamine and Mortality in Sepsis
The aim of this retrospective study was to identify if the enrolled patient might have had a profit of Cytosorb therapy. Primarily the decline in catecholamine therapy under Cytosorb therapy will be investigated.
- Conditions
- Sepsis, Septic Shock, Cytokine Storm, Cytokine Release Syndrome
- Trial name
- NCT04567199
- Testing
- Observational, retrospective
- Where
- Austria
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Medical University Innsbruck
Cytokine Release Syndrome, Sepsis
Cytokine Removal With CVVHD Compared to CVVH
Septic patients with acute kidney injury (SA-AKI) requiring continuous renal replacement therapies (CRRT) present high mortality due to systemic inflammatory response, cytokine liberation, and finally multiorgan dysfunction.
- Conditions
- Cytokine Release Syndrome, Sepsis, AKI
- Trial name
- NCT04048525
- Testing
- CVVHD, CVVH
- Where
- 2 sites in Spain
- Volunteers
- 40 people
- Sponsor
- Hospital Universitari de Bellvitge